Equilis Te
Adjuvanted vaccine against tetanus
Table of contents
Overview
Equilis Te is a veterinary vaccine used to protect horses from six months of age against tetanus to prevent mortality. Tetanus is an acute, often fatal disease caused by a neurotoxin produced by the bacterium Clostridium tetani. The disease, which usually originates from contaminated wounds, is characterised by overall rigidity (stiffness) and convulsive spasms of the muscles. Horses belong to the most susceptible species to tetanus. It contains the active substance tetanus toxoid.
Authorisation details
Product details | |
---|---|
Name |
Equilis Te
|
Agency product number |
EMEA/V/C/000093
|
Active substance |
tetanus toxoid
|
International non-proprietary name (INN) or common name |
Adjuvanted vaccine against tetanus
|
Species |
Horses
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI05AB03
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
8
|
Date of issue of marketing authorisation valid throughout the European Union |
08/07/2005
|
Contact address |
Intervet International B.V.
Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands |
Product information
20/05/2019 Equilis Te - EMEA/V/C/000093 - IG/1104
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for equidae
Therapeutic indication
Active immunisation of horses from 6 months of age against tetanus to prevent mortality.
Onset of immunity: 2 weeks after the primary vaccination course
Duration of immunity: 17 months after the primary vaccination course, 24 months after the first revaccination